{"filings":[{"id":999917,"accession_number":"0001104659-26-072931","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2026-06-11T20:05:35+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"TELA Bio shareholders approve 3.5M share equity plan increase, elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 3,500,000 share increase to 2019 Equity Incentive Plan; total authorized shares now 10,932,620.","Joseph Capper, Betty Jo Rocchio, and William Plovanic elected as Class I directors until 2029.","KPMG LLP ratified as independent auditor for fiscal 2026 with 33.4M votes for, 17,890 against.","Non-binding advisory vote on named executive officer compensation passed: 20.9M for, 6.9M against.","Plan amendment prohibits repricing of options/SARs without stockholder approval and extends plan term to 10 years from April 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40442,"accession_number":"0001104659-26-059393","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2026-05-12T20:11:00+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.","Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.","Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.","Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.","U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93656,"accession_number":"0001104659-26-053102","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","5.02"],"status":"ready","headline":"TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.","Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, Federica O'Brien to resign after 2026 annual meeting.","Board nominates Joseph Capper (CEO of MiMedx) for election as Class I director and future Chairman.","Board appoints Guido Neels, Guy Nohra, Paul Thomas as new directors effective after 2026 annual meeting.","Incoming directors and Capper to receive initial equity awards: options for 17,550 shares and RSUs for 11,925 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105460,"accession_number":"0001104659-26-033839","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).","Net loss Q4 2025 $9.0M vs $9.2M prior year; FY net loss $38.8M vs $37.8M.","Closed $70M credit facility from Perceptive Advisors; $60M drawn at closing, $10M option by Apr 2027.","Promoted Howard Langstein, MD, FACS to Chief Medical Officer effective March 1, 2026.","FY 2026 revenue guidance: at least 8% growth; Q1 2026 revenue expected ~$18.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105459,"accession_number":"0001104659-26-032697","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TELA Bio receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified TELA on March 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.","Company has until September 14, 2026 to regain compliance by closing at $1.00 for 10 consecutive days.","Stock continues trading on Nasdaq Global Market under symbol TELA; no immediate delisting effect.","If not cured by September 14, TELA may transfer to Nasdaq Capital Market for a second 180-day cure period.","Company says it will monitor bid price and consider options to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121742,"accession_number":"0001104659-25-112653","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"TELA Bio secures $70M Perceptive term loan and launches approximately $11.9M equity offering; terminates MidCap facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$60M initial loan funded Nov 14, 2025; optional $10M delayed draw. Matures Nov 14, 2030. Interest: 7.85% margin + greater of Reference Rate or 4.25%.","Issued Perceptive warrants for up to 2,333,333 shares at $1.11 exercise price, expiring 2035; warrants are cashless-exercisable and freely transferable.","Registered direct offering: 4,189,000 common shares and 7,523,000 pre-funded warrants at $1.11/$1.1099; expected net proceeds of ~$11.9M for general corporate purposes, closing Nov 17, 2025.","Terminated Credit & Security Agreement with MidCap Financial Trust; all MidCap security interests released.","Minimum liquidity covenant of $5.0M; revenue covenant specified in agreement; post-closing condition: company must receive at least $8.5M gross from equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121741,"accession_number":"0001104659-25-111285","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.","Full-year 2025 revenue guidance revised to at least 16% growth over 2024.","Closed $70M credit facility from Perceptive Advisors: $60M initial draw, $10M accordion; interest rate 7.85%+greater of Term SOFR or 4.25%, interest-only to Nov 2030.","Appointed Betty Jo Rocchio and Bill Plovanic to the Board of Directors."],"consensus_eps_estimate":-0.203,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":59406000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121740,"accession_number":"0001104659-25-105548","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TELA Bio appoints William Plovanic to board; expands board to seven members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from six to seven members; Plovanic appointed as Class I director through 2026 annual meeting.","Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity; also former CEO/CFO of Obalon Therapeutics.","Received initial equity grant: option for 17,550 shares (36-month vest) and RSU for 11,925 shares (3-year vest).","Annual board retainer of $45,000; will receive annual equity awards starting at 2026 meeting (11,700 options + 7,950 RSUs).","Plovanic is independent under Nasdaq rules; no related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121739,"accession_number":"0001104659-25-098354","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TELA Bio board changes: Lisa Colleran resigns, Dr. Betty Jo Rocchio appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Colleran resigned from the board on Oct 4, 2025; no disagreement with company.","Dr. Betty Jo Rocchio appointed effective Oct 9, 2025; she is EVP, Chief Executive Nurse at Advocate Health.","Initial equity award: option for 17,550 shares vesting monthly over 3 years; RSU for 11,925 shares vesting annually over 3 years.","Annual retainer $45,000; starting 2026: annual award of option for 11,700 shares and RSU for 7,950 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138412,"accession_number":"0001104659-25-076153","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.","Net loss $9.9M vs $12.6M in prior-year quarter; operating loss $9.1M improved from $11.6M.","Gross margin improved to 69.8% vs 68.8% due to lower excess/obsolete inventory charge.","Appointed Jeffrey Blizard as President effective June 2025 to strengthen commercial leadership.","Reaffirmed FY2025 revenue guidance of $85M-$88M (23-27% YoY growth); cash $35.0M."],"consensus_eps_estimate":-0.1803,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":38717000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155872,"accession_number":"0001104659-25-055248","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Blizard resigned from Board effective June 2, 2025; no disagreement with company.","Blizard appointed President effective same date; Antony Koblish remains CEO, drops President title.","Annual base salary $475,000; target bonus 50% of salary; cash sign-on $150,000.","Equity grant: 154,100 stock options (4-yr vest) and 104,800 RSUs (4-yr annual vest).","Blizard previously Global Head of Surgical Sales at Abiomed (J&J); joined TELA Bio board June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155871,"accession_number":"0001104659-25-054867","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"TELA Bio stockholders approve 3.5M share increase to equity plan and officer liability limitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Blizard, Burgess, O'Brien elected; Burgess received only 9.75M votes for vs 19.54M withheld.","Equity plan amendment approved (20.03M for, 9.25M against); adds 3.5M shares, removes evergreen provision.","Charter amendment to limit officer liability passed (23.84M for, 5.41M against).","Non-binding say-on-pay approved with 23.03M for; annual frequency selected (26.94M for 1-year).","KPMG LLP ratified as auditor for 2025 with 31.84M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155870,"accession_number":"0001104659-25-046124","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.","Net loss $11.3M vs $5.7M; operating loss $10.5M (prior-year included $7.6M asset sale gain).","Cash $42.8M; reiterates FY2025 revenue guidance $85-88M (23-27% growth), opEx flat YoY.","Full U.S. launch of larger OviTex PRS for plastic/reconstructive surgery commenced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":18520000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174330,"accession_number":"0001104659-25-029612","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches larger OviTex PRS sizes for plastic/reconstructive surgery","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Larger sizes include 25x30 cm oval and 25 cm diameter circle, the largest option on the market.","OviTex PRS is the only reinforced polymer-suture tissue matrix for plastic/reconstructive surgery.","Nearly 15,000 units sold since 2019; 31% YoY unit growth in 2024.","New configurations aim to reduce need for multiple smaller pieces and simplify complex procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174329,"accession_number":"0001104659-25-026142","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.","FY2024 net loss narrowed to $37.8M from $46.7M in 2023; Q4 net loss $9.2M vs $12.9M a year ago.","FY2025 revenue guidance $85-88M (23-27% growth); Q1 2025 revenue expected $17-18M (2-8% growth).","Operating expenses step down Q3 to Q4; management targets 2025 OpEx flat vs 2024.","OviTex IHR product for inguinal hernia repair launched mid-April 2024, sold over 1,200 units in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191278,"accession_number":"0001104659-24-115317","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.","Net loss $10.4M vs $11.0M loss in Q3 2023; operating loss $9.4M vs $10.2M.","Gross margin 68% vs 69% YoY due to higher excess/obsolete inventory charge.","Closed public offering yielding ~$46M gross proceeds; cash $17.3M at Sept 30.","Expects $5M-$10M reduction in 2025 operating expenses from H1 2024 annualized; reiterates FY2024 revenue guidance $74.5M-$76.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":51651000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191277,"accession_number":"0001104659-24-110891","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TELA Bio prices $37.3M public offering of 12M shares and pre-funded warrants at $2.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 12M shares at $2.25/share and 5.8M pre-funded warrants at $2.2499 each, exercisable at $0.0001.","Net proceeds expected ~$37.3M after underwriting discounts and expenses; use for general corporate purposes including sales, marketing, R&D.","Underwriters have a 30-day option to purchase up to an additional 2.67M shares.","Pre-funded warrants are immediately exercisable; exercise price $0.0001; beneficial ownership cap of 9.99% or 4.99% at holder's election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191276,"accession_number":"0001104659-24-110552","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.","Gross margin ~68% vs 69% in prior-year quarter.","Cash and equivalents $17.3M at Sept 30, 2024, down from $46.7M at Dec 31, 2023.","Cost-cutting measures expected to reduce FY2025 operating expenses by $5M-$10M annualized."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":51651000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207767,"accession_number":"0001104659-24-088353","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.","FY 2024 revenue guidance reiterated at $74.5M-$76.5M (27%-31% YoY growth).","Appointed Greg Firestone as CCO on May 20 to boost commercial productivity.","Launched robotically compatible OviTex IHR for inguinal hernia market in U.S.","Expects $3M-$7M in total NIVIS revenue share payments over next eight quarters starting Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":32694000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225239,"accession_number":"0001104659-24-069099","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"TELA Bio appoints Jeffrey Blizard to Board; stockholders re-elect directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Blizard, Global Head of Surgical Sales at Abiomed (J&J MedTech), appointed to Board as Class III director, term to 2025 annual meeting.","Initial equity grant: option for 9,300 shares vesting monthly over 36 months and RSU for 6,375 shares vesting in three annual installments.","Annual retainer: $45,000 for Board service plus $5,000 for Nominating Committee.","Stockholders elected Kurt Azarbarzin (17,037,112 for) and Antony Koblish (18,742,180 for) as Class II directors; KPMG ratified as auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225238,"accession_number":"0001104659-24-063416","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio appoints Greg Firestone as CCO, replaces Peter Murphy terminated without cause","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Greg Firestone appointed Chief Commercial Officer effective May 20, 2024; previously Chief Business Officer since October 2017.","Peter Murphy terminated as CCO without cause on May 19, 2024; will receive severance per his employment agreement.","Firestone will oversee commercial operations, product launches, sales training, and market access strategy.","Firestone brings 35+ years of healthcare experience, including founding the IDN Summit & Expo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225237,"accession_number":"0001104659-24-059355","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q1 revenue $16.6M (+39% YoY); raises FY2024 guidance to $74.5M-$76.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.6M, up 39% YoY; 13th consecutive quarter of ≥35% growth.","OviTex revenue +31% YoY; OviTex PRS +54% YoY.","Gross margin improved to 68% vs 66% last year; net loss narrowed to $5.7M from $12.0M.","FY2024 revenue guidance raised to $74.5M-$76.5M (27-31% YoY growth).","Appointed Howard N. Langstein as VP of Medical Affairs; launched Robotic-Compatible OviTex IHR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":16603000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225236,"accession_number":"0001104659-24-046970","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.","Builds on OviTex portfolio with >45,000 implantations and 8 years clinical experience.","Study on 259 patients using ReBAR technique showed low 1.2% recurrence rate at 1.5-year follow-up.","Designed for laparoscopic and robotic-assisted repair; aims to address shortcomings of permanent synthetic mesh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244448,"accession_number":"0001104659-24-037296","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"TELA Bio reports record 2023 revenue $58.5M (+41% YoY); guides FY2024 $74-76M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $17.0M (+46% YoY); full-year revenue $58.5M (+41% YoY).","Net loss $12.9M in Q4, $46.7M for FY 2023; cash $46.7M at year-end.","FY 2024 revenue guidance $74-76M (27-30% YoY growth).","Launched LIQUIFIX FIX8 and Precision, FDA-approved liquid adhesive for hernia mesh fixation.","Sold NIVIS distribution rights to MiMedx for $8-12M cash consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244447,"accession_number":"0001104659-24-036394","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.","Total consideration at least $8M and up to $12M from MiMedx for the wound care product.","NIVIS is an absorbent collagen matrix indicated for wound management and minor bleeding.","TELA to focus on hernia repair and reconstructive surgery products, including new LIQUIFIX and OviTex configurations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261894,"accession_number":"0001104659-23-116264","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.","OviTex hernia mesh now #1 biologic mesh in U.S. by unit volume.","OviTex PRS revenue grew 46% YoY; commercial launch of Long-Term Resorbable variant.","Q3 net loss $11.0M vs. $10.7M a year ago; cash $58.2M at quarter end.","Updated FY2023 revenue guidance to $57-60M (38-45% YoY growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":41455000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261893,"accession_number":"0001104659-23-110478","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"TELA Bio extends HQ lease to 2030, adds 15,881 sq ft of space","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Fourth Amendment to Lease for corporate headquarters in Malvern, PA.","Lease term extended from May 31, 2028 to May 31, 2030.","Adds 15,881 sq ft from Dec 1, 2023, total leased to 40,606 sq ft; will later reduce by 4,652 sq ft on June 30, 2025.","Monthly base rent starts at $49,403.97, increases annually; after July 2025 base rent $45,841.35.","Space houses R&D, controlled environment room, and office operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279066,"accession_number":"0001104659-23-104741","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Board member John Nosenzo resigns from TELA Bio board effective Sept 22, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Nosenzo resigned from TELA Bio's Board of Directors on September 22, 2023.","He also resigned from the Audit and Nominating and Corporate Governance Committees.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279065,"accession_number":"0001104659-23-092205","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches OviTex PRS Long-Term Resorbable for plastic and reconstructive surgery","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OviTex PRS Long-Term Resorbable is intended for soft tissue repair or reinforcement in plastic and reconstructive surgery.","Product supplements existing OviTex PRS portfolio which includes Permanent and Short-Term Resorbable configurations.","Features include bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.","OviTex PRS has over 6,800 implantations at more than 400 healthcare facilities.","CEO Antony Koblish says addition allows surgeons to address indications requiring longer term reinforcement without permanent materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279064,"accession_number":"0001104659-23-089299","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.","Gross margin improved to 70% vs 63% in Q2 2022 due to better inventory management.","Net loss $10.8M, narrower than $12.7M loss in prior-year quarter.","FY2023 revenue guidance reaffirmed: $60-65M, representing 45-57% growth.","Cash $65.3M after underwritten public offering netting ~$46.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":26403000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297392,"accession_number":"0001104659-23-067533","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TELA Bio stockholders elect Lisa Colleran and Doug Evans as Class I directors; ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lisa Colleran elected with 14,316,642 votes for and 1,055,675 withheld; Doug Evans with 13,535,182 for and 1,837,135 withheld.","Ratification of KPMG as independent auditor for FY2023 passed with 17,188,505 for, 3,312 against, 1,957 abstentions.","Total shares outstanding at April 5, 2023 record date: 19,227,777; broker non-votes on director election: 1,821,457."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297391,"accession_number":"0001104659-23-059119","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q1 revenue $11.9M (+45% YoY); reaffirms FY2023 guidance $60M-$65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.9M, up 45% YoY; OviTex revenue +42%, OviTex PRS +52%.","Gross margin improved to 66% from 61% due to better inventory management.","Net loss $12.0M vs $10.9M; operating loss $11.3M vs $9.8M.","Closed public offering netting ~$46.4M; cash $30.1M at quarter end.","Reaffirms FY2023 revenue guidance $60M-$65M (45-57% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":11909000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297390,"accession_number":"0001104659-23-047844","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TELA Bio announces public offering of 4.75M shares at $9.50 per share; expects net proceeds ~$42.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 4,750,000 shares at $9.50 per share; underwriters have 30-day option for 712,500 additional shares.","Net proceeds expected ~$42.1 million after underwriting discounts and estimated expenses.","Use proceeds for general corporate purposes including sales, marketing, R&D, working capital, and capex.","Offering expected to close April 21, 2023, subject to customary conditions.","Underwriting agreement with Jefferies, Piper Sandler, and Lake Street Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297389,"accession_number":"0001104659-23-046698","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"TELA Bio preliminary Q1 revenue $11.9M, up 45% YoY; cash $30.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue estimated at $11.9M for Q1 2023 vs $8.2M in Q1 2022, a 45% increase.","Cash and equivalents $30.1M at March 31, 2023, down from $42.0M at Dec 31, 2022.","Results are preliminary and subject to change upon completion of quarter-end closing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":11909000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317739,"accession_number":"0001104659-23-035822","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio receives FDA 510(k) clearance for OviTex PRS Long-Term Resorbable","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance on March 23, 2023 for OviTex PRS Long-Term Resorbable.","Product reinforces soft tissue in plastic and reconstructive surgery where weakness exists.","Complements existing OviTex PRS Permanent and Short-Term Resorbable configurations.","Design features bi-directional stretch and a fully resorbable long-term polymer.","CEO Antony Koblish states it expands clinical utility and demonstrates tunable design capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317738,"accession_number":"0001104659-23-035061","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.","Q4 2022 gross margin 70% vs 68% a year ago; cash $42.0M at Dec 31.","OviTex revenue +26% YoY; OviTex PRS +92% YoY; new NIVIS and OviTex LPR launches.","FY2023 revenue guidance $60-65M (45-57% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317737,"accession_number":"0001104659-23-023518","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches two larger OviTex LPR configurations for large abdominal hernia repair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 15x20 cm and 15x25 cm ellipse sizes for ventral and incisional hernias.","Designed for robotic and laparoscopic ports; low profile facilitates minimally invasive placement.","In prior quarter, 40% of OviTex cases were robotic and 20% laparoscopic.","OviTex LPR initially commercialized in 2018; new sizes expand product portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317736,"accession_number":"0001104659-23-002441","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TELA Bio furnishes updated investor slide deck; no specific financial or operational disclosures provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed a current report under Item 7.01 to furnish an updated corporate slide deck dated January 10, 2023.","The slide deck is attached as Exhibit 99.1 and will be used in meetings with investors.","No quantitative updates, guidance changes, or material events were disclosed in the filing text or the provided exhibit excerpt.","The filing states the slides are furnished, not filed, and are not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317735,"accession_number":"0001104659-23-002053","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches NIVIS Fibrillar Collagen Pack for surgical wound management","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NIVIS is an absorbent matrix of Type I and Type III bovine collagen for moderately to heavily exudating wounds and minor bleeding.","The product complements the OviTex portfolio and expands TELA's soft-tissue preservation offerings.","Commercial launch follows an exclusive development and distribution partnership with Collagen Matrix, Inc. announced in April 2022.","NIVIS is provided in particulate form to be molded and packed into wounds, facilitating contact with host tissue.","Product targets general, plastic, and reconstructive surgery markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336005,"accession_number":"0001104659-22-116468","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.","Net loss $10.7M vs $8.3M; operating loss $9.5M vs $7.2M in Q3 2021.","Reaffirmed FY2022 revenue guidance $42-45M (43-53% growth over FY2021).","OviTex revenue +29% YoY, OviTex PRS +108% YoY; BRAVO study shows 2.6% recurrence rate.","Closed August oversubscribed public offering netting $34.4M; cash $54.2M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":29796000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336004,"accession_number":"0001104659-22-111340","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.","OviTex 1S Permanent demonstrated a 2.6% hernia recurrence rate at 24 months via open, laparoscopic, or robotic techniques.","Patient quality-of-life showed statistically significant improvement from baseline at 3, 12, and 24 months.","Surgical site occurrences in 38% of patients; 78% were high-risk (obesity, smoking, COPD, diabetes, etc.).","CEO states commitment to ongoing BRAVO II study evaluating OviTex in robot-assisted repairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353410,"accession_number":"0001104659-22-092239","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TELA Bio (TELA) raises ~$34.2M in public offering of 4.6M shares at $8.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement with Lake Street Capital Markets for 4M shares at $8.00/share; option for 600K additional shares exercised in full.","Net proceeds expected to be approximately $34.2 million after underwriting discounts and offering expenses.","Proceeds intended for working capital, general corporate purposes, including R&D, manufacturing, and potential acquisitions.","Offering expected to close on August 18, 2022, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353409,"accession_number":"0001104659-22-090443","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TELA Bio furnishes investor slide deck; no specific financial figures in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing includes a corporate slide deck dated August 15, 2022 for investor meetings.","No earnings, guidance, or operational metrics disclosed in the 8-K or exhibit text.","Deck is furnished under Regulation FD; not filed or incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353408,"accession_number":"0001104659-22-088622","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.","Net loss widened to $12.7M from $8.3M; operating loss $10.2M vs $7.3M.","FY2022 revenue guidance $42-45M (43-53% growth); COVID could impact.","Cash $27.7M at June 30; secured up to $50M debt facility from MidCap Financial.","Entered GPO contract with Premier Inc. covering ~4,400 hospitals, effective October 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":18637000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371122,"accession_number":"0001104659-22-067626","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TELA Bio stockholders elect all three Class III directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vince Burgess, Federica O'Brien, and John Nosenzo elected as Class III directors with >10.7M votes each.","Ratification of KPMG LLP as independent auditor passed with 13,084,355 votes for, 124,770 against.","Annual Meeting held virtually on June 1, 2022; 14,556,750 shares outstanding as of record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371121,"accession_number":"0001104659-22-066225","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"TELA Bio enters $50M credit facility with MidCap; repays $33.2M OrbiMed debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $40.0M upfront from $50.0M term loan facility; unused $10M Tranche 2 conditional on reaching $65M net revenue by FY2023.","Repaid outstanding $33.2M under existing OrbiMed credit agreement.","Loan bears interest at 6.25% plus one-month Term SOFR (floor 1.0%), matures May 1, 2027.","Interest-only for 36 months, extendable to 48 months subject to covenant compliance; then amortization.","Prepayment fee 3% in year one, 2% year two, 1% year three; plus 5% exit fee on principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371120,"accession_number":"0001104659-22-058223","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q1 revenue $8.2M (+40% YoY); net loss widens to $10.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue grew 40% YoY to $8.2M; OviTex PRS revenue up 111% YoY.","Gross margin improved to 61% from 59% on lower excess/obsolete inventory adjustments.","Net loss $10.9M vs $8.1M; operating loss $9.8M vs $7.3M.","Cash and equivalents $33.0M; FY2022 revenue guidance reaffirmed at $40-45M.","Appointed D. Taylor Ocasio as General Counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":8231000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390110,"accession_number":"0001104659-22-036114","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).","Q4 net loss $8.6M vs $7.8M; FY net loss $33.3M vs $28.8M.","Gross margin improved to 68% in Q4; full-year 64%.","Cash $43.9M at Dec 31, 2021.","FY2022 revenue guidance $40-$45M; preliminary Q1 2022 revenue ~$8.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390109,"accession_number":"0001104659-22-029676","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TELA Bio launches SiteGuard No Rinse Antimicrobial Solution for plastic reconstructive surgery","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SiteGuard uses Next Science's XBIO Technology to deconstruct biofilm and provide over 5 hours of protection.","TELA Bio entered exclusive distribution agreement in November 2021 to market the wash in US plastic reconstructive surgery.","First adjunctive soft-tissue technology complementing TELA's soft-tissue preservation and restoration product portfolio.","CEO Antony Koblish cites encouraging early test market experience and plans for nationwide expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390108,"accession_number":"0001104659-22-000943","cik":1561921,"company_name":"TELA Bio, Inc.","ticker":"TELA","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TELA Bio appoints Megan Smeykal as Chief Accounting Officer effective Jan 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Megan Smeykal, age 46, promoted from VP – Corporate Controller to Chief Accounting Officer.","She joined TELA Bio in Dec 2019 as VP of Financial Reporting; prior VP at Nutrisystem 2006–2019.","Started accounting career at Arthur Andersen (1997–2002); holds CPA license in Pennsylvania.","No family relationships with directors/officers; no transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40737191.9447641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-04T23:59:59+00:00|390108"}